PDS Biotechnology (PDSB) Short Interest Ratio & Short Volume $1.15 -0.05 (-4.17%) Closing price 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDS Biotechnology Short Interest DataPDS Biotechnology (PDSB) has a short interest of 2.88 million shares, representing 6.94% of the float (the number of shares available for trading by the public). This marks a 44.72% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.6, indicating that it would take 5.6 days of the average trading volume of 476,197 shares to cover all short positions.Current Short Interest2,880,000 sharesPrevious Short Interest1,990,000 sharesChange Vs. Previous Month+44.72%Dollar Volume Sold Short$3.83 millionShort Interest Ratio5.6 Days to CoverLast Record DateJune 30, 2025Outstanding Shares45,710,000 sharesShort Percent of Float6.94%Today's Trading Volume289,150 sharesAverage Trading Volume476,197 sharesToday's Volume Vs. Average61% Short Selling PDS Biotechnology? Sign up to receive the latest short interest report for PDS Biotechnology and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPDSB Short Interest Over TimePDSB Days to Cover Over TimePDSB Percentage of Float Shorted Over Time PDS Biotechnology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20252,880,000 shares $3.83 million +44.7%6.9%5.6 $1.33 6/15/20251,990,000 shares $3.48 million -31.4%4.8%4.1 $1.75 5/31/20252,900,000 shares $3.94 million +0.7%8.6%6.2 $1.36 5/15/20252,880,000 shares $3.89 million -3.0%8.5%3.9 $1.35 4/30/20252,970,000 shares $4.16 million -1.0%N/A4.9 $1.40 4/15/20253,000,000 shares $3.33 million -4.5%8.9%4.9 $1.11 3/31/20253,140,000 shares $3.74 million -18.7%9.3%5.1 $1.19 3/15/20253,860,000 shares $4.75 million -17.3%11.4%6.3 $1.23 2/28/20254,670,000 shares $6.21 million +20.7%13.8%7.4 $1.33 2/15/20253,870,000 shares $6.04 million -3.5%11.4%9.8 $1.56 Get the Latest News and Ratings for PDSB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. 1/31/20254,010,000 shares $6.58 million -2.4%N/A10.6 $1.64 1/15/20254,110,000 shares $5.96 million +1.2%N/A10.3 $1.45 12/31/20244,060,000 shares $6.62 million -4.0%N/A10.1 $1.63 12/15/20244,230,000 shares $7.78 million +9.0%N/A9.5 $1.84 11/30/20243,880,000 shares $8.50 million +0.3%N/A9.2 $2.19 11/15/20243,870,000 shares $7.78 million -13.4%N/A9.9 $2.01 10/31/20244,470,000 shares $14.26 million -6.9%N/A14.3 $3.19 10/15/20244,800,000 shares $15.50 million +0.2%N/A16.1 $3.23 9/30/20244,790,000 shares $18.30 million +3.9%N/A14.2 $3.82 9/15/20244,610,000 shares $13.83 million -3.2%N/A11.2 $3.00 8/31/20244,760,000 shares $15.23 million -5.4%N/A10.7 $3.20 8/15/20245,030,000 shares $16.25 million -0.8%N/A10.4 $3.23 7/31/20245,070,000 shares $18.05 million -11.1%N/A8.8 $3.56 7/15/20245,700,000 shares $24.08 million -18.6%N/A9.1 $4.23 6/30/20247,000,000 shares $20.51 million +3.7%N/A10.4 $2.93 6/15/20246,750,000 shares $18.80 million +0.6%N/A8.7 $2.79 5/31/20246,710,000 shares $20.00 million -2.0%N/A8.2 $2.98 5/15/20246,850,000 shares $23.98 million -0.2%N/A7.3 $3.50 4/30/20246,860,000 shares $22.98 million -3.9%N/A7.6 $3.35 4/15/20247,140,000 shares $20.13 million +16.1%N/A7.7 $2.82 3/31/20246,150,000 shares $24.35 million +11.6%N/A6.7 $3.96 3/15/20245,510,000 shares $27.00 million +9.5%N/A7 $4.90 2/29/20245,030,000 shares $33.15 million +0.4%N/A7.1 $6.59 2/15/20245,010,000 shares $27.35 million -5.1%N/A8.4 $5.46 1/31/20245,280,000 shares $28.25 million +1.9%N/A8.6 $5.35 1/15/20245,180,000 shares $22.38 million +5.5%N/A9.2 $4.32 12/31/20234,910,000 shares $24.40 million +4.7%N/A9.8 $4.97 12/15/20234,690,000 shares $23.92 million -3.5%N/A9 $5.10 11/30/20234,860,000 shares $25.56 million -7.4%N/A9.9 $5.26 11/15/20235,250,000 shares $33.18 million -4.9%N/A11.3 $6.32The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 10/31/20235,520,000 shares $23.02 million -6.3%N/A12 $4.17 10/15/20235,890,000 shares $26.56 million +11.8%N/A12.3 $4.51 9/30/20235,270,000 shares $26.61 million +15.3%N/A9.9 $5.05 9/15/20234,570,000 shares $24.40 million +6.5%N/A7.9 $5.34 8/31/20234,290,000 shares $25.18 million +7.8%N/A6.4 $5.87 8/15/20233,980,000 shares $23.40 million +0.5%N/A3.9 $5.88 7/31/20233,960,000 shares $22.63 million -5.5%N/A4.3 $5.72 7/15/20234,190,000 shares $21.49 million +8.0%N/A4.7 $5.13 6/30/20233,880,000 shares $19.52 million +32.0%N/A4.5 $5.03 6/15/20232,940,000 shares $18.29 million +9.7%N/A3.5 $6.22 5/31/20232,680,000 shares $25.67 million +27.0%N/A3.9 $9.58 5/15/20232,110,000 shares $14.62 million No ChangeN/A6.1 $6.93 4/30/20232,110,000 shares $12.83 million +3.4%N/A5.9 $6.08 4/15/20232,040,000 shares $14.06 million +2.5%N/A4.9 $6.89 3/31/20231,990,000 shares $12.24 million +7.6%N/A4.3 $6.15 3/15/20231,850,000 shares $12.27 million +1.7%N/A3.1 $6.63 2/28/20231,820,000 shares $13.92 million +15.2%N/A3 $7.65 2/15/20231,580,000 shares $13.84 million -3.7%N/A2.5 $8.76 1/31/20231,640,000 shares $13.66 million +9.3%N/A1.6 $8.33 1/15/20231,500,000 shares $15.57 million +5.6%N/A1.5 $10.38 12/30/20221,420,000 shares $18.74 million +34.0%N/A1.4 $13.20 12/15/20221,060,000 shares $10.01 million -2.8%N/A1.3 $9.44 11/30/20221,090,000 shares $9.84 million -26.4%N/A1.4 $9.03 11/15/20221,480,000 shares $12.85 million +5.7%N/A2.1 $8.68 10/31/20221,400,000 shares $7.34 million +6.9%N/A5.7 $5.24 10/15/20221,310,000 shares $5.23 million +0.8%N/A5.4 $3.99 9/30/20221,300,000 shares $3.86 million -6.5%N/A5.9 $2.97 9/15/20221,390,000 shares $5.45 million -6.1%N/A6 $3.92 8/31/20221,480,000 shares $6.20 million -1.3%N/A5.3 $4.19 8/15/20221,500,000 shares $8.69 million -10.2%N/A2.4 $5.79 7/31/20221,670,000 shares $7.15 million -5.1%N/A2.5 $4.28 7/15/20221,760,000 shares $7.00 million -6.9%N/A2.7 $3.98 6/30/20221,890,000 shares $6.90 million +0.5%N/A3 $3.65 6/15/20221,880,000 shares $6.07 million +20.5%N/A3 $3.23 5/31/20221,560,000 shares $6.12 million +4.0%N/A2.6 $3.92 5/15/20221,500,000 shares $6.84 million +2.0%N/A5.6 $4.56 4/30/20221,470,000 shares $8.13 million +1.4%N/A5.8 $5.53 4/15/20221,450,000 shares $8.12 million +0.7%N/A4.6 $5.60 3/31/20221,440,000 shares $8.91 million +0.7%N/A4.2 $6.19 3/15/20221,430,000 shares $7.81 million +14.4%N/A4 $5.46 2/28/20221,250,000 shares $7.48 million +50.7%N/A3.2 $5.98 2/15/2022829,500 shares $5.72 million +32.5%N/A2.1 $6.90 1/31/2022625,900 shares $3.73 million -5.5%N/A1.5 $5.96 1/15/2022662,000 shares $4.51 million +4.8%N/A1.8 $6.82 12/31/2021631,600 shares $5.12 million -10.6%N/A1.7 $8.10 12/15/2021706,800 shares $6.34 million +33.4%N/A1.7 $8.97 11/30/2021529,800 shares $5.22 million -26.5%N/A1.2 $9.85 11/15/2021720,300 shares $7.86 million -6.7%N/A1.6 $10.91 10/29/2021772,000 shares $9.29 million -5.0%N/A1.6 $12.04 10/15/2021812,700 shares $10.02 million +66.2%N/A1.7 $12.33The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 9/30/2021489,100 shares $7.29 million +10.2%N/A1 $14.90 9/15/2021443,900 shares $6.79 million -1.6%N/A0.8 $15.30 8/31/2021451,100 shares $7.01 million +11.9%2.0%0.5 $15.55 8/13/2021403,200 shares $4.29 million -19.3%1.8%0.4 $10.65 7/30/2021499,600 shares $5.33 million -18.7%2.3%0.3 $10.67 7/15/2021614,500 shares $6.00 million -26.5%2.9%0.3 $9.77 6/30/2021836,400 shares $10.50 million -31.4%4.2%0.5 $12.55 6/15/20211,220,000 shares $11.22 million +20.8%5.6%0.7 $9.20 5/28/20211,010,000 shares $12.32 million +18.8%5.7%0.5 $12.20 5/14/2021850,500 shares $3.81 million +27.8%N/A0.4 $4.48 4/30/2021665,600 shares $3.80 million -29.0%N/A0.4 $5.71 4/15/2021937,100 shares $4.92 million +207.3%N/A0.6 $5.25 3/31/2021305,000 shares $1.30 million -62.6%N/A0.2 $4.25 3/15/2021816,300 shares $4.61 million +73.6%N/A0.5 $5.65 2/26/2021470,300 shares $2.09 million +38.8%N/A0.5 $4.45 2/12/2021338,900 shares $1.90 million -26.2%N/A0.4 $5.61 1/29/2021458,900 shares $1.18 million +19.2%N/A0.6 $2.57 1/15/2021385,100 shares $1.06 million -40.7%N/A0.8 $2.76 12/31/2020648,900 shares $1.45 million +39.4%N/A1.4 $2.23 12/15/2020465,400 shares $981.99 thousand +8.1%N/A1 $2.11 11/30/2020430,400 shares $912.45 thousand +10.5%N/A0.9 $2.12 11/15/2020389,600 shares $798.68 thousand +10.9%N/A1 $2.05 10/30/2020351,300 shares $751.78 thousand +66.8%N/A0.6 $2.14 10/15/2020210,600 shares $494.91 thousand -32.1%N/A0.3 $2.35 9/30/2020310,000 shares $722.30 thousand -42.8%N/A0.3 $2.33 9/15/2020542,000 shares $1.36 million -22.9%N/A0.3 $2.51 8/31/2020702,900 shares $1.71 million +0.8%N/A0.4 $2.43 8/14/2020697,200 shares $1.95 million -1.5%N/A0.4 $2.79 7/31/2020708,100 shares $2.59 million +4.9%N/A0.4 $3.66 PDSB Short Interest - Frequently Asked Questions What is PDS Biotechnology's current short interest? Short interest is the volume of PDS Biotechnology shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 2,880,000 shares of PDSB short. 6.94% of PDS Biotechnology's shares are currently sold short. Learn More on PDS Biotechnology's current short interest. What is a good short interest ratio for PDS Biotechnology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PDSB shares currently have a short interest ratio of 6.0. Learn More on PDS Biotechnology's short interest ratio. Which institutional investors are shorting PDS Biotechnology? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of PDS Biotechnology: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for PDS Biotechnology? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.94% of PDS Biotechnology's floating shares are currently sold short. Is PDS Biotechnology's short interest increasing or decreasing? PDS Biotechnology saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,880,000 shares, an increase of 44.7% from the previous total of 1,990,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does PDS Biotechnology's short interest compare to its competitors? 6.94% of PDS Biotechnology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to PDS Biotechnology: MediWound Ltd. (11.95%), biote Corp. (2.97%), Larimar Therapeutics, Inc. (10.24%), Canopy Growth Corporation (10.18%), AC Immune (2.31%), Neumora Therapeutics, Inc. (16.13%), 4D Molecular Therapeutics, Inc. (9.29%), Eupraxia Pharmaceuticals Inc. (0.62%), Ventyx Biosciences, Inc. (0.01%), Organigram Global Inc. (6.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short PDS Biotechnology stock? Short selling PDSB is an investing strategy that aims to generate trading profit from PDS Biotechnology as its price is falling. PDSB shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against PDS Biotechnology? A short squeeze for PDS Biotechnology occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PDSB, which in turn drives the price of the stock up even further. How often is PDS Biotechnology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PDSB, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies MediWound Short Squeeze biote Short Squeeze Larimar Therapeutics Short Squeeze Canopy Growth Short Squeeze AC Immune Short Squeeze Neumora Therapeutics Short Squeeze 4D Molecular Therapeutics Short Squeeze Eupraxia Pharmaceuticals Short Squeeze Ventyx Biosciences Short Squeeze Organigram Global Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PDSB) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PDSB Stock Alerts